Bristol Myers Squibb Expands DTC Channel with Discounted Psoriasis Drug, Enhancing Patient Access

What's Happening?

Bristol Myers Squibb (BMS) has announced the expansion of its direct-to-consumer (DTC) sales channel in the United States by adding its psoriasis therapy, Sotyktu (deucravacitinib). This move follows the initial inclusion of the anticoagulant Eliquis in July. The DTC channel offers significant discounts for patients who can pay out-of-pocket, with Sotyktu available at over 80% off its usual price, reducing the cost from nearly $7,000 to $950 for a 30-day supply. The BMS Patient Connect platform aims to make medications more accessible and affordable, providing delivery across the U.S. and Puerto Rico, along with patient support resources. This initiative is part of a broader trend in the pharmaceutical industry, as companies like Eli Lilly, Novo Nordisk, and Pfizer also explore DTC models to address market pressures and enhance transparency.

Why It's Important?

The expansion of BMS's DTC channel is significant as it reflects a shift in the pharmaceutical industry's approach to drug distribution. By bypassing traditional channels like wholesalers and pharmacy benefit managers, BMS can offer competitive pricing directly to consumers, potentially increasing access to essential medications. This model could lead to reduced out-of-pocket costs for patients, particularly those with chronic conditions like psoriasis. However, it also raises concerns about the influence on prescriber behavior and data privacy. The move could set a precedent for other pharmaceutical companies, potentially reshaping the market dynamics and patient experience in the U.S. healthcare system.

What's Next?

BMS plans to potentially expand the DTC model to other medications deemed suitable for this approach. The company is also seeking FDA approval for Sotyktu as a treatment for psoriatic arthritis and is conducting late-stage trials for other conditions. As the DTC model gains traction, it may prompt regulatory scrutiny and discussions about the implications for patient privacy and market competition. Stakeholders, including healthcare providers and policymakers, will likely monitor the impact of this distribution strategy on drug pricing and access.

Beyond the Headlines

The shift to a DTC model by pharmaceutical companies like BMS could have long-term implications for the healthcare industry. It challenges the traditional roles of pharmacy benefit managers and could lead to increased competition among drug manufacturers. Additionally, the model's success may depend on maintaining patient trust and ensuring data privacy, as direct interactions with consumers could expose sensitive health information. The ethical considerations of influencing prescriber behavior and the potential for increased medication adherence are also areas of interest.